SoftWave OrthoGold 100 is SoftWave Tissue Regeneration's entry in the shockwave category, built on Unfocused Electrohydraulic Shockwave. The platform treats chronic musculoskeletal pain, soft tissue injuries, wound healing, with 5-10 minutes per area and a recommended course of 3-6 sessions. FDA cleared in 2018, it lists in the $50,000-$95,000 range for new units and $25,000-$50,000 on the secondary market.
Electrohydraulic unfocused shockwave that covers a treatment zone roughly 10x larger than focused shockwave per shot. The OrthoGold 100 is built by MTS Medical in Germany and distributed in the US by SoftWave TRT. SoftWave markets the device around tissue regeneration and stem cell activation claims. Per-session pricing runs $150-$500, which is at the high end of the shockwave category, supported by premium positioning and scarcity of authorized practices in most markets. The mechanism is what separates SoftWave OrthoGold 100 from competitors in the same category. Where it fits in your practice depends on patient demographics, treatment volume, and whether you need a flagship platform or a value-tier alternative.
SoftWave OrthoGold 100 is manufactured by SoftWave Tissue Regeneration (Alpharetta, GA, founded 2015). The device benefits from SoftWave Tissue Regeneration's long manufacturer history and presence across US-focused. Service support, training availability, and parts access vary by region. Practices considering this device should validate dealer presence and technical support coverage in their area before signing a contract.
Scarcity of authorized practices in most markets reduces local competition
MTS Medical Germany engineering with strong component quality
Fast-growing US chiropractic and integrative medicine installed base
Cons
Stem cell activation marketing claims face ongoing regulatory scrutiny from FDA
Electrode replacement costs ($1,000-$3,000/year) run higher than radial alternatives
Thinner peer-reviewed evidence base than focused or radial shockwave platforms
SoftWave TRT distribution model limits authorized practice density in some regions
Cash-pay only: no insurance CPT reimbursement pathway
Clinical Evidence
15+ published studies on unfocused electrohydraulic shockwave for musculoskeletal applications. Evidence base is thinner than focused or radial alternatives. Most published studies come from European institutions. The SoftWave mechanism differs from focused shockwave, so the broader shockwave literature does not directly apply. Independent IRB-approved US trials are limited. The published evidence base for SoftWave OrthoGold 100 reflects how long the platform has been in market and how much the manufacturer has invested in clinical research. Devices with FDA clearance dates before 2018 typically have stronger peer-reviewed datasets than newer entrants. For physicians evaluating this device, the questions worth asking are whether the studies used blinded evaluators, what the sample sizes were, and whether the research was independent or manufacturer-funded.
Compare SoftWave OrthoGold 100's evidence base against the category benchmark. In SoftWave OrthoGold 100's category, the strongest evidence typically comes from devices that have been on the market for at least five years and have multiple randomized controlled trials with independent funding. Marketing claims from any manufacturer should be cross-checked against PubMed-indexed publications rather than conference posters or white papers. Conference presentations are not equivalent to peer review.
For practices that require strong clinical evidence (academic dermatology, plastic surgery groups with research interests, multi-physician practices that need to defend purchase decisions internally), the evidence profile should be a top-three decision factor. For high-volume cash-pay practices where patient demand drives device selection, brand recognition often matters more than the underlying evidence base. Both approaches are defensible, but they lead to different device selections.
ROI Analysis
Practice ROI for SoftWave OrthoGold 100 depends on three variables: capital cost, per-session revenue, and treatment volume. At a new unit price of $50,000-$95,000, financed over five years at typical equipment rates, the monthly payment runs roughly 2-2.5% of total cost. Per-session revenue at $150-$500 means the device needs to fill enough treatment slots monthly to cover the payment, consumables ($1,000-$3,000), maintenance ($3,000-$6,500), and operator labor.
For a practice doing 2-3 treatments per day at the midpoint of the per-session range, SoftWave OrthoGold 100 typically reaches break-even at 12-18 months for the lower end of the new pricing range, or 18-30 months at the high end. Used and refurbished units in the $25,000-$50,000 range can cut payback periods in half. The biggest practice mistake is over-projecting treatment volume. Physicians who run their numbers on 4-6 daily treatments rarely hit those targets in year one.
The realistic question is not whether SoftWave OrthoGold 100 can pay back. Most devices in this price range do, eventually. The question is whether your practice can fill the schedule. Practices with existing patient flow in Physical Therapy, Orthopedics have the easiest path. Practices building demand from scratch should plan for 6-12 months of marketing investment before the device pays for itself.
Best For
Chiropractic, regenerative medicine, and integrative practices that can charge premium cash-pay pricing and want territory scarcity from SoftWave TRT's authorized-practice model. Practices whose patient base responds to stem cell and tissue regeneration positioning. The fit is strongest for practices that match the device's positioning on price, clinical evidence requirements, and patient throughput expectations. Practices with mismatched economics often regret these purchases within 18 months.
Beyond practice type, SoftWave OrthoGold 100 fits best when the patient base aligns with the device's strengths. For shockwave platforms, this usually means matching device capability to patient demographics, skin type range, and willingness to pay per-session pricing. Practices in markets where patients price-shop heavily need to factor that into device selection. Practices in concierge or luxury markets can charge premium pricing that justifies premium platforms.
Buying Guide
New SoftWave OrthoGold 100 units sell for $50,000-$95,000 from SoftWave Tissue Regeneration or authorized dealers. Refurbished and used units sell for $25,000-$50,000 on the secondary market. The decision between new and used comes down to warranty coverage, software version, included applicators, and consumable allowances. New units typically include a 12-24 month warranty, current software, all applicators, and a starter consumable package. Used units usually carry no warranty, may have outdated software, and require separate consumable purchases.
What to negotiate: applicator quantity (always ask for additional applicators thrown in), consumable starter packs, training and certification fees, extended warranty coverage, marketing materials, and clinical training for additional providers. SoftWave Tissue Regeneration sales reps typically have 10-15% list price flexibility and far more on bundled deals. End-of-quarter and end-of-year are the strongest negotiation windows. Trade-in programs for older devices can reduce net cost by another 10-20%.
What to watch for: software lock-out fees on used units (some manufacturers disable software on resold devices), per-pulse or per-treatment licensing fees that show up after purchase, consumable price increases over the device life, and service contract terms. Always require a written quote that breaks out hardware, applicators, training, first-year service, and consumables separately. Bundled quotes hide the line items where margins live.
Alternatives and Comparisons
The main alternatives to SoftWave OrthoGold 100 in this category are listed below. Click into any comparison for a full side-by-side breakdown.
DUOLITH SD1: Sports medicine practices and orthopedic clinics that want the most versatile shockwave platform. Practices that see complex tendinopathies requiring focused th
MASTERPULS MP200: Physical therapy, chiropractic, and sports medicine practices that need radial shockwave at a moderate capital cost. Practices building a dedicated shockwave se
Swiss DolorClast: Academic sports medicine programs, high-volume physical therapy clinics, and research-oriented practices that need to reference peer-reviewed evidence when defe
Chattanooga RPW: Physical therapy clinics that want entry-level radial shockwave capability with familiar Chattanooga service and training. Practices adding shockwave to an exis
New SoftWave OrthoGold 100 units sell for $50,000-$95,000 from SoftWave Tissue Regeneration and authorized dealers. Used and refurbished units typically run $25,000-$50,000 on the secondary market depending on age, software version, and included applicators. Per-session pricing for treatments is $150-$500. Annual consumables run $1,000-$3,000 and annual maintenance averages $3,000-$6,500. Practices financing the device should expect monthly payments around 2-2.5% of the total purchase price over a five-year term.
Is SoftWave OrthoGold 100 FDA cleared?
Yes. SoftWave OrthoGold 100 received FDA 510(k) clearance in 2018. The clearance covers the indications listed in the device labeling. Off-label uses are common in clinical practice but should be discussed with patients explicitly. Physicians should verify current clearance status and any updates directly with SoftWave Tissue Regeneration or via the FDA 510(k) database before making a purchase decision.
What is the clinical evidence behind SoftWave OrthoGold 100?
15+ published studies on unfocused electrohydraulic shockwave for musculoskeletal applications. Evidence base is thinner than focused or radial alternatives. Most published studies come from European institutions. The SoftWave mechanism differs from focused shockwave, so the broader shockwave literature does not directly apply. Independent IRB-approved US trials are limited. When evaluating clinical evidence, look for blinded evaluator studies, independent funding sources, and peer-reviewed publications rather than manufacturer-funded white papers or conference posters. Evidence quality varies widely between devices in the same category, even when the marketing materials look similar.
Which specialties use SoftWave OrthoGold 100?
SoftWave OrthoGold 100 is primarily used by Physical Therapy, Orthopedics, Sports Medicine, Urology, Podiatry. Best fit varies by patient mix and practice economics. Chiropractic, regenerative medicine, and integrative practices that can charge premium cash-pay pricing and want territory scarcity from SoftWave TRT's authorized-practice model. Practices whose patient base responds to stem cell and tissue regeneration positioning.
How long does a SoftWave OrthoGold 100 treatment session take?
Each SoftWave OrthoGold 100 treatment session runs 5-10 minutes per area. The recommended protocol is 3-6 sessions. Total chair time including consultation, setup, treatment, and post-treatment care is typically 1.5-2x the listed treatment time. Practices planning daily treatment volume should use the realistic chair-time number, not just the active treatment minutes.
What are the main pros and cons of SoftWave OrthoGold 100?
Strengths: Large unfocused treatment zone speeds up multi-area sessions; Premium per-session pricing ($150-$500) protects gross margins; Scarcity of authorized practices in most markets reduces local competition. Weaknesses: Stem cell activation marketing claims face ongoing regulatory scrutiny from FDA; Electrode replacement costs ($1,000-$3,000/year) run higher than radial alternatives; Thinner peer-reviewed evidence base than focused or radial shockwave platforms. Every device in this category has tradeoffs. The right choice depends on which strengths matter most to your practice and which weaknesses you can tolerate.
What does SoftWave OrthoGold 100 cost to operate annually?
Annual operating costs for SoftWave OrthoGold 100 include consumables ($1,000-$3,000), maintenance and service ($3,000-$6,500), and operator labor. Practices doing high treatment volumes should also budget for additional applicator wear and replacement. Total annual operating cost typically runs 5-15% of the original purchase price, with consumables driving most of the variability between low and high estimates.
Who manufactures SoftWave OrthoGold 100 and how stable is the company?
SoftWave OrthoGold 100 is manufactured by SoftWave Tissue Regeneration, headquartered in Alpharetta, GA and founded in 2015. The company is privately held and operates in US-focused countries. Annual revenue is approximately Not disclosed (private). Manufacturer financial stability matters because it affects warranty support, parts availability, and long-term software updates. Physicians making capital purchases should always check the manufacturer's recent financial trajectory before committing.
What does SoftWave OrthoGold 100 cost in 2026?
As of April 2026, SoftWave OrthoGold 100 new unit pricing is $50,000-$95,000 from SoftWave Tissue Regeneration and authorized dealers. Refurbished and used unit pricing typically runs $25,000-$50,000 on the secondary market. Per-session treatment pricing for patient billing is $150-$500. Pricing has held relatively stable through 2025-2026 across the shockwave category, though specific applicator and consumable pricing varies. Practices should request current quotes directly from SoftWave Tissue Regeneration sales for the most accurate 2026 pricing because list price varies meaningfully by region, configuration, and trade-in deals.
How does SoftWave OrthoGold 100 compare to other shockwave devices in 2026?
In the 2026 shockwave category, SoftWave OrthoGold 100 competes primarily with the other devices reviewed on DevicePulse: masterpuls, duolith, swiss-dolorclast, chattanooga-rpw. The differentiation comes down to clinical evidence depth, treatment time per session, applicator versatility, and total cost of ownership over a 5-year period. Most practices choose between 2-3 finalists based on specialty mix, patient volume, and existing equipment compatibility. Run a side-by-side total cost of ownership analysis before committing to a capital purchase.
What is the SoftWave OrthoGold 100 treatment protocol and recommended session count?
The SoftWave OrthoGold 100 recommended treatment protocol is 3-6 sessions, with each session running 5-10 minutes per area. Total treatment plan duration depends on the indication and patient response. For patient pricing and ROI calculations, multiply per-session pricing ($150-$500) by the recommended session count to get the patient-facing treatment course cost. Practices typically build the treatment plan into a package price rather than billing per session, which improves patient retention through the full protocol.
What's the latest news and updates for SoftWave OrthoGold 100 in 2026?
As of April 2026, SoftWave OrthoGold 100 continues commercial availability from SoftWave Tissue Regeneration. Recent industry updates relevant to the device include manufacturer financial disclosures, new clinical evidence publications, software updates, and FDA labeling changes. SoftWave Tissue Regeneration shares periodic business updates that inform the long-term outlook for SoftWave OrthoGold 100 support and continued investment. Check the manufacturer's investor relations page or press releases for the most current operational status.
Get Device Pulse every Tuesday
Weekly price tracker, FDA clearances, safety signals, and clinical evidence summaries. The only newsletter built for physicians who buy equipment.